Kidney perfusion: some like it hot others prefer to keep it cool. by Jochmans, I et al.
1 
 
Ex-situ kidney perfusion: some like it hot others prefer to keep it cool 
Authors 
Ina Jochmans (1,2), Sarah Hosgood (3) 
Affiliations 
(1) Lab of Abdominal Transplant Surgery, Department of Microbiology and Immunology, KU Leuven, 
Leuven, Belgium 
(2) Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium 
(3) Department of Surgery, Addenbrooke's Hospital, University of Cambridge, United Kingdom 
 
Corresponding author 
Ina Jochmans 
Abdominal Transplant Surgery 
University Hospitals Leuven 
Herestraat 49 
3000 Leuven 
Belgium 
E-mail: ina.jochmans@uzleuven.be  
Phone: +32-16-348727 
Fax: +32-16-348743 
 
Funding 
None   
2 
 
Abstract 
Purpose of review 
Machine perfusion technologies provide an opportunity for improved preservation, organ 
assessment and resuscitation of damaged kidneys. This review summaries the recent advancements 
in hypothermic and normothermic kidney machine perfusion technologies. 
Recent Findings 
Modifications to the perfusion conditions with the addition of oxygen during hypothermic machine 
perfusion can support a low level of metabolism which, in experimental settings, improves graft 
function. Normothermic machine perfusion technologies are evolving in different directions either 
for short resuscitation, more prolonged periods of perfusion, and the transition between 
hypothermic and normothermic conditions are being investigated. Clinical trials are ongoing in both 
hypothermic and normothermic settings. 
Functional parameters can be used to assess kidney quality and although normothermic machine 
perfusion may hold an advantage over hypothermic machine perfusion, new metabolomics, 
proteomic, and genomic technologies may be applied in the future to both technologies to provide 
more rigorous information on kidney quality.  
Promoting recovery by introducing an intervention during perfusion is an attractive area of research 
and therapies targeting the endothelium are a particular area of interest. 
Summary 
A great deal of research is still needed to optimise and logistically place hypothermic and 
normothermic perfusion technologies. In the future, we may progress towards organ-tailored 
preservation whereby high-risk kidneys can undergo assessment and repair before transplantation. 
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Introduction 
Ex-situ kidney perfusion – also called machine perfusion (MP) – has been the topic of increased 
research over the past decade. Driven by the need to optimise preservation, assess graft viability, 
and repair damaged kidney grafts, a multitude of strategies for ex-situ perfusion have been 
developed. Hypothermic (HMP) and normothermic MP (NMP) have been studied quite intensively 
and are finding their way into clinical practice [1*]. 
We review recent developments and explore the future of these technologies. 
Preservation 
Ex-situ perfusion instead of static cold storage (SCS) might improve preservation. 
 
Hypothermic 
Data from randomised controlled trials and several meta-analyses have provided good evidence 
showing a reduction of delayed graft function (DGF) with HMP in brain dead donor kidneys [2-6*]. 
Although meta-analyses seem to support this finding in kidneys donated after circulatory death 
(DCD) [4], the two largest randomized controlled trials in DCDs contradict each other. One shows 
DGF reduction with HMP while the other does not [7,8]. Ongoing clinical trials might provide 
additional evidence [1*]. 
More data are needed focusing on the effect of HMP on long-term graft function and survival 
[1*,9*]. An improved 1 and 3-year graft survival after HMP, most pronounced in kidneys from 
expanded criteria donors (ECD) has been shown [10,11]. But this effect is not present in DCD kidneys 
[7,8,10]. Also, a clear benefit of HMP on relatively rare outcomes, such as primary non-function, has 
not been shown. 
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Normothermic 
The clinical application of NMP has recently emerged. The report on NMP in a series of 17 ECD 
kidneys is the largest to date [12]. NMP showed a significant reduction in DGF compared to a 
matched cohort of SCS-kidneys (4% vs 36%, respectively). NMP is designed to resuscitate the kidney 
after SCS. NMP is carried out for 1h whilst the patient is being prepared for transplantation. After 
NMP, the kidney is flushed with cold preservation solution and placed back on ice until 
transplantation [13]. A multicentre randomized controlled trial in DCD category III/IV kidneys is 
ongoing in the UK (ISRCTN15821205). The trial will randomize kidneys to NMP (n=200) or SCS 
(n=200) and is due to end in 2020. 
There is no survival data available on NMP. 
Refinement 
Hypothermic conditions are designed to suppress metabolism and negate the need for oxygenation. 
Whereas, normothermic conditions restore cellular metabolism and therefore require oxygen.  
 
Hypothermia 
It is not known how HMP exerts its beneficial effects but perfusion likely helps maintain a healthy 
endothelium and replenish ATP; it might even alter the organ’s immunogenicity [14,15*,16*]. 
Increased nitric oxide–dependent vasodilation and improved cortical microcirculation at reperfusion 
regulated through improved endothelial nitric oxide synthase phosphorylation has been 
demonstrated in HMP-preserved DCD porcine kidneys [17]. Moreover, a degree of vascular shear 
stress, critical for normal vascular function, is maintained by the flow during HMP. This could have 
an anti-inflammatory effect through activation of flow-dependent genes [18,19]. 
Modifying HMP conditions towards supporting metabolism by adding oxygen is compelling. 
Oxygenation during HMP restores ATP content in the kidney [20,21*]. In the liver, oxygenated HMP 
reversibly suppresses mitochondrial oxidative metabolism after SCS. Mitochondrial release of 
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reactive oxygen species at reperfusion is decreased with deactivation of numerous intracellular and 
extracellular pathways, including the inflammatory response [14,22]. There is some evidence to 
support a similar hypothesis in kidneys [21*]. Preclinical studies have shown improvement of graft 
function after oxygenated HMP, particularly in DCD kidneys [20,23-26]. The effect of oxygenated 
HMP is being investigated in two randomized clinical trials, one in DCD (ISRCTN32967929), the other 
in ECD (ISRCTN63852508) which will finish in 2018 [1*]. 
 
Normothermia 
ATP replenishment, which prevents further breakdown of metabolites and restores cellular function, 
is likely to be the key component of protection during NMP [27]. NMP also upregulates protective 
mechanisms (e.g. heat shock protein 70) that aid regeneration and repair [27]. Restoration of 
circulation at a near-physiological pressure is likely to be beneficial to the endothelium maintaining 
critical shear stress levels  
There is little information on the optimal NMP perfusate and apart from the acellular perfusate 
described by Brasile et al [28,29], recent techniques use a packed red blood cell based solution 
[12,30*,31**]. The red cells can be suspended in crystalloid [12] or Steen solution [30*]. 
NMP systems typically use a super-physiological concentration of oxygen (95%) balanced with 
carbon dioxide to ensure optimal oxygenation and acid based balance. Nonetheless, in a highly 
oxygenated environment there is the danger of promoting reactive oxygen species production and 
inducing oxidative damage. Kron et al, demonstrated that an increased release of injury markers (8-
OHdG, HMGB-1) into the perfusate and more TLR-4 positive cells suggesting more oxidative stress 
during NMP in a rodent model [21]. NMP of liver report the application of air balanced with 
physiological levels of oxygen to maintain acid base homeostasis [32*]. Research in the kidney to 
determine the optimal oxygen concentration is underway. 
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Assessment 
The ability to assess a kidney and predict the outcome has been a major area of research. Ex-situ 
perfusion gives information on flow and renal resistance characteristics. Sampling of the perfusate 
allows the measurement of injury or function which could be informative. 
 
Hypothermia 
There is no good evidence to suggest that accurate assessment of kidney viability during HMP is 
possible. Previous work has shown that an association between perfusion characteristics – such as 
flow and renal resistance – exists. Higher resistance is an independent risk factor for the 
development of DGF [33] and primary non function [34]. Importantly, however, the predictive value 
of the renal resistance is too low for it to be used as a single and reliable viability measure. Similar 
evidence exists for commonly used injury markers such as glutathione S-transferase, lactate 
dehydrogynase, heart-type fatty acid binding protein, redox-active iron, IL-18, and neutrophil 
gelatinase-associated lipocalin (NGAL) [35]. Despite being an independent risk factor for DGF [36] 
and primary non-function [37], the associations and predictive capacity of any determined cut-off 
were too low to be of any help at the individual kidney-recipient level. Recent work from the US 
adds to the evidence that perfusion dynamics and currently identified injury markers are not useful 
diagnostic tools when considered on their own. In a large prospective study Parikh et al studied the 
relationship between several perfusate markers (NGAL, liver-type fatty acid binding protein, IL-18, 
and kidney injury molecule-1), renal resistance and flow, and outcome in 671 kidneys preserved by 
HMP. Perfusate NGAL and liver-type fatty acid binding protein measured near the end of HMP as 
well as resistance and flow were only modestly associated with 6 month estimated glomerular 
filtration rate (eGFR) [38*]. 
With the emergence of new technologies such as metabolomics, proteomics, and genomics it might 
be that in the future a (set of) viability markers might still be identified. As an example, Guy et al 
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have recently shown that 28 different metabolites varied in concentration throughout HMP. 
Leucine, inosine, gluconate, and glucose predicted DGF, with areas under the curve above 0.70 
[39*]. Additional evidence of ongoing metabolism during HMP has been shown in porcine kidneys 
[40**]. Perhaps focusing on metabolic activity and potential to recuperate function instead of trying 
to quantify the extent on injury will prove more successful as a viability tool. 
 
Normothermia 
With the restoration of metabolism and function, assessment during NMP has a major advantage 
over hypothermic techniques. Measures of function (renal blood flow and urine output) in 
combination with the macroscopic appearance during NMP can be used to formulate a simple 
scoring system [41*]. Preliminary results showed that DGF was more frequent and eGFR at 12 
months lower in kidneys with a higher injury score [41*]. To test these criteria we have set up a 
research study to assess and transplant kidneys that have been declined for transplantation by all UK 
centers. So far, 3 kidneys have been successfully transplanted as part of this program [42**]. 
Changes potassium and lactate in the perfusate and urinary biomarkers such as NGAL and 
endothelin-1 appear to reflect damage but their prediction on outcome remains to be determined 
[43*]. As with HMP, metabolomics, proteomics, and genomics approaches may also prove 
informative in the future. 
Targeted treatment and Repair 
An appealing quality of ex-situ perfusion is the administration of therapeutic agents solely to the 
organ pre-transplantation. This avoids unwanted systemic effects from administering these agents 
to the patient and obviates problems with targeting organ specific cells. The applications could 
include use of stem cell and gene therapy to target complex issues such as rejection and fibrosis. 
 
Hypothermia 
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Hypothermia reduces active metabolism substantially – and intentionally – thereby likely minimising 
any potential effect of drugs targeted to repair damage that has already happened. Nevertheless, a 
recent porcine study showed that thrombalexin – a conjugate peptide of the direct thrombin 
inhibitor – adheres to the endothelium when given during HMP. Kidneys treated with thrombalexin 
had increased blood flow during whole blood normothermic reperfusion which mimics 
transplantation. Although no markers of kidney function or injury were measured and additional 
research is needed, this study shows that targeted treatment under hypothermic conditions might 
be possible [44*]. 
 
Normothermia 
NMP may provide a more obvious and beneficial platform for therapy delivery as the kidney is in a 
functioning state. This allows close monitoring of the effects and the isolated study of mechanisms 
and therapeutic actions of treatment agents. 
Using human kidneys, Brasile et al demonstrated effective transfection of a recombinant adenovirus 
with an encoded GFP reporter protein delivered during NMP [45]. Gene-silencing techniques can 
also be used to promote cell survival [46]. In collaboration with Yale University, preliminary work is 
underway by our group to assess the uptake of endothelium targeted nanoparticles using NMP in 
declined human kidneys. 
Another growing area of interest is the use of mesenchymal stem cells (MSCs). Although MSCs are 
notable for their differentiation properties, which modulate tissue repair and regeneration, their 
immunomodulatory and paracrine properties, such as anti-apoptotic and anti-fibrotic effects, make 
them attractive in the transplant setting [47*]. Experimental studies using different models of kidney 
injury with MSCs have demonstrated amelioration in kidney function reduced tubular injury, and 
prolonged survival following ischemia-reperfusion injury. 
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Implementation 
Successful implementation of any technology relies on the ability to accommodate the logistics of 
transportation of the organ from donor to recipient center. This has led to several questions 
concerning the timing of HMP and NMP techniques. Should perfusion be carried out continuously or 
at the beginning, middle, or the end of the preservation interval (Fig. 1).  
 
Hypothermia 
The contradicting results of HMP in DCD kidneys from the most recent two randomized controlled 
trials might be related to the setting in which HMP is used. In the Eurotransplant MP-Trial, kidneys 
were placed on the HMP device at the donor center, immediately after retrieval [7]. In the UK trial, 
those kidneys retrieved away from the transplant center were cold stored during transfer after 
which HMP was started [8]. As such, it could be that HMP needs to be used in a continuous setting 
to achieve a benefit. 
 
Normothermic 
The preliminary results of a short resuscitation period using NMP are encouraging. Nonetheless, 
more prolonged periods of perfusion may be advantageous. In a DCD porcine kidney model 16h of 
NMP resulted in improved function compared to 16h SCS or 15h SCS followed by 1h NMP or 8h SCS 
and 8h NMP [31**]. 
There is also some evidence that an intermediate period of NMP may be beneficial. We reported a 
single case whereby the kidney underwent 1h NMP after SCS. Normally the second cold ischemic 
period after NMP is short but due to adverse circumstances the kidney was placed back on ice for 5 
hours [48]. Nevertheless, it was transplanted successfully with no adverse effects and immediate 
graft function. 
  
Hypothermia to normothermic 
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The transition from hypothermia to normothermia has been a topic of interest in the last few years. 
Minor et al, used controlled oxygenated rewarming [49*]. After a period of SCS porcine kidneys 
were gradually rewarmed to 20°C over a period of 90 minutes. At reperfusion kidney function was 
improved, oxidative damage and inflammatory gene expression were lower. This appears to be a 
promising move forward in the combined use of HMP and NMP techniques. 
 
Future 
For any new technology to become widely implemented it would not only need to show benefit but 
it would also need to be cost-beneficial. Ex-situ kidney perfusion as a strategy should therefore be 
affordable and the cost balanced against the expected benefits and the number needed to treat to 
achieve those benefits. In addition to the machines, disposables, perfusate, and personnel time are 
needed. The cost of these vary depending on the type of ex-situ perfusion used. Invariably those of 
NMP will be higher as it relies on more complicated equipment and – at least in its current setting – 
needs continuous supervision. 
The adaptability of ex-situ kidney perfusion seems endless. Not only can we vary temperature and 
perfusate but also the timing (Fig. 1) and length of perfusion can be changed as well as the addition 
of numerous potential additives to either improve preservation or elicit repair. Furthermore, there 
are literality multiple combinations of the ‘basic’ ex-situ perfusion techniques possible (e.g. HMP 
followed by a short period of NMP for assessment purposes). In this quickly advancing field it will 
become increasingly important for the transplant community to retain oversight of the progress and 
developments and to identify the next important questions to answer. With only a finite number of 
transplants performed each year and large numbers needed to conduct appropriately powered trials 
as well as a number of organ preservation strategies that could ‘compete’ with each other, national 
and international collaboration and perhaps prioritisation has never been more important or 
challenging. 
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We envision the use of ex-situ kidney perfusion as an organ-tailored preservation, diagnostic, and 
treatment technology where the temperature or combination of temperatures depends on the risk 
estimate of a particular kidney (Fig. 2). The identification of what defines a high-risk and injured 
kidney and which parameters specific to ex-situ preservation can provide additional information 
should be a priority. Next, the ideal settings for assessment and repair need to be defined. These 
settings might be different for different types of kidneys – as is becoming clear from the evidence on 
HMP where the effects seem different depending on organ type. Perhaps that HMP (or oxygenated 
HMP) will provide a ‘preservation mode’ before the kidney goes on to ‘assessment mode’ during a 
short period of NMP. If repair is needed, it could go on to ‘repair mode’ targeting specific areas of 
the kidney depending on the injury perceived to be present (e.g. in kidneys with acute tubular 
necrosis in the donor this might be mainly tubular damage, in DCDs it might be endothelial 
activation, …).  
Conclusion 
Ex-situ perfusion opens many doors to advance kidney preservation but a lot of questions remain 
unanswered and even unidentified. We need to assemble the evidence, target key questions in 
unified international efforts and identify the populations that would benefit most from the different 
possible ex-situ preservation settings or combination of these settings. 
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Key points 
 Hypothermic machine perfusion reduces the risk of delayed graft function and might 
improve outcome in a subgroup of donor kidneys 
 There is no quality evidence to support the use of hypothermic machine perfusion 
characteristics or perfusate injury markers as stand-alone tools to assess kidney viability 
 Normothermic machine perfusion shows promising results as an assessment and 
resuscitation tool 
 Organ tailored preservation – using ex situ perfusion in a variety of modes – is the future 
 Efforts to improve preservation should be directed and unified international efforts are 
needed to advance the field 
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Figure legends 
Figure 1. Different applications of hypothermic and normothermic kidney perfusion technologies 
1: Hypothermic or normothermic perfusion (MP) for the entire preservation interval 
2: A short period of MP at the donor hospital followed by static cold storage (SSCS) for 
transportation to the recipient center. 
3: End MP at the recipient center.  
4: An intermittent period of MP which may be in an organ hub or at the recipient center. After 
perfusion kidneys are placed back in SSCS. 
 
Figure 2. Tailored preservation protocol.  
